Product Pipeline

Akari’s development pipeline is focused on inhibitors of early mediators of acute and chronic inflammation, specifically the complement system, the eicosanoid system and the bioamine system. Each of these systems have either proven or scientifically well-supported causative roles in the diseases being targeted by Akari. Akari believes that blocking early mediators of inflammation will prevent initiation and continual amplification of the processes that cause certain diseases.

All Akari molecules are derived from ticks through 300 million years of natural selection have evolved to produce inhibitors that bind tightly to key highly-conserved inflammatory mediators, are well tolerated in humans, and remain fully functional when a host is repeatedly exposed to the molecule.

Akari Pipeline